Q2 and H1 revenues grew significantly year-over-year, driven by strong launches of TRYNGOLZA and DAWNZERA. TRYNGOLZA's sHTG launch is progressing well, with expanding payer coverage and robust demand, while DAWNZERA continues to gain share in HAE prophylaxis.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.